Andrew J. Armstrong, MD, and colleagues looked at men with metastatic castration-resistant prostate cancer treated with sipuleucel-T in the PROCEED registry. Study findings demonstrated that African-American men experienced a substantially greater survival benefit from the immunotherapy than Caucasian men.
Vinayak Muralidhar, MD, and colleagues compared a subgroup of men with favorable high-risk PCa (T1c with either a Gleason score of 4+4 = 8 and a PSA level below 10 ng/mL or a Gleason score of 6 and a PSA level greater than 20 ng/mL) with standard high-risk disease.
Karen E. Hoffman, MD, MHSc, MPH, and colleagues examined the comparative harms of contemporary treatments for localized prostate cancer through 5 years in favorable and unfavorable risk patients.
David F. Friedlander, MD, MPH, and his colleagues examined facility-level variation in the performance of pelvic lymphadenectomy during radical prostatectomy for high-risk prostate cancer and its effect on overall survival.
Renal & Urology News discussed the annual LUGPA meeting with Mara R. Holton, MD, who sits on LUGPA’s board of directors and is the organization’s vice chair of health policy.
Dr Provenzano has conducted extensive research on the management of anemia in patients with kidney disease.
Dr Adam B. Weiner led a study evaluating temporal trends and factors associated with the use of surgical castration for men with de novo metastatic prostate cancer.
Dr Agarwal led the phase 2 AMBER study, which looked at the effectiveness of the oral potassium binder patiromer on the persistence of spironolactone use in patients with advanced chronic kidney disease (CKD) and resistant hypertension.
Amar U. Kishan, MD, and Jad Chahoud, MD, MPH, discuss their strategies for managing metastatic castration-sensitive prostate cancer.
Brian T. Helfand, MD, PhD, discussed germline testing for prostate cancer prognosis and its implications for active surveillance at the Philadelphia Prostate Cancer Consensus Conference: Implementation of Genetic Testing for Inherited Prostate Cancer.
How does this procedure compare with other ablative therapies for prostate cancer? Where does the research go from here? Find out what this expert had to say about a new method for treating prostate cancer.
What should be the basis for starting non-metastatic CRPC patients on one of the novel anti-androgens?
At the 2019 annual meeting of the American Urological Association (AUA), Dr Jarrard was a member of the instructional faculty in a session titled “AUA Castration Resistant Prostate Cancer (CRPC) Guidelines and Therapeutic Advances in Metastatic Prostate Cancer.”
Expert perspective on some of the important developments in prostate cancer management from the AUA 2019 meeting.
Is testosterone replacement in men with prostate cancer safe?
Should brachytherapy be used more than it is for localized prostate cancer?
What are the adverse effects related to the use of medications for advanced prostate cancer?
What is the best approach for treating patients with cT4 prostate cancer?
What is the role of race in prostate cancer treatment decisions?
What is the top goal of ureteroscopy (URS)?
Want to read more?
Please login or register first to view this content.
Next post in Expert Perspectives